Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 4, 2014, Pages 641-644

  McAdoo, Stephen P ^a,b   Pusey, Charles D ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; HUMORAL IMMUNE DEFICIENCY; LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; SYSTEMATIC REVIEW; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B LYMPHOCYTE; DRUG EFFECTS; FEMALE; MALE;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 84922286095     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01270214     Document Type: Editorial

References (27)

1. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220, 2010
2. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vas-culitis. N Engl J Med 363: 221–232, 2010
3. Guerry MJ, Brogan P, Bruce IN, D’Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR: Recommendations for the use ofrituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51: 634–643, 2012
4. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488–494, 2011
5. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R: Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials [published online ahead of print November 15, 2013]. Ann Rheum Dis doi:10.1136/annrheumdis-2013-203927
6. Pendergraft WF 3rd, Cortazar FC, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL: Long-term maintenance therapy using rituximab-induced continuous B cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9: 736–744, 2014
7. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR: Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64: 3760–3769, 2012
8. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L; on behalf of the French Vasculitis Study Group: Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients [published online ahead of print November 26, 2013]. Rheumatology (Oxford) doi:10.1093/rheumatology/ ket381
9. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U: Rituximab for remission induction and maintenance in refractory gran-ulomatosis with polyangiitis (Wegener’s): Ten-year experience at a single center. Arthritis Rheum 64: 3770–3778, 2012
10. Besada E, Koldingsnes W, Nossent JC: Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre. Rheumatology (Oxford) 52: 2041–2047, 2013
11. Knight A, Hallenberg H, Baecklund E: Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis-A case series [published online ahead of print August 20, 2013]. Clin Rheumatol doi:10.1007/s10067-013-2351-y
12. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369: 417–427, 2013
13. Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, Feller AC, Pitann S, Gause A, Gross WL: B lymphocyte maturation in Wegener’s granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65: 859–864, 2006
14. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310–317, 2009
15. Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P: The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 123: 5098–5103, 2013
16. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469, 2005
17. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955–960, 2012
18. Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, Cairns T, Cook HT, Pusey CD, Salama AD: Prolonged disease-free remission following rituximab and low-dose cyclophos-phamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 26: 3280–3286, 2011
19. Charles P, Guillevin L: S3. Rituximab for ANCA-associated vasculitides: The French experience. Presse Med 42: 534–536, 2013
20. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613–620, 2006
21. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P: B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 63: 3038–3047, 2011
22. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH: Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 8: 382–391, 2013
23. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54: 723–732, 2006
24. Holden NJ, Williams JM, Morgan MD, Challa A, Gordon J, Pepper RJ, Salama AD, HarperL,Savage CO:ANCA-stimulated neutrophils release BLyS and promote B cell survival: A clinically relevant cellular process. Ann Rheum Dis 70: 2229–2233, 2011
25. Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, Lyons PA, Smith KG, Pusey CD, Cook HT, Salama AD: Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int 83: 1150–1158, 2013
26. McKinney, EF, Lyons, PA, Carr, EJ, Hollis, JL, Jayne, DR, Willcocks, LC, Koukoulaki, M, Brazma, A, Jovanovic, V, Kemeny, DM, Pollard, AJ, Macary, PA, Chaudhry, AN, Smith, KG: A CD81 T cell transcription signature predicts prognosisin autoimmune disease. Nat Med 16: 586–591, 2010
27. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener’s gran-ulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–105, 2008